tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
PremiumRatingsPromising SEQUOIA-HCM Study Data Justifies Buy Rating for Cytokinetics
2M ago
Cytokinetics presents additional data related to Aficamten
Premium
The Fly
Cytokinetics presents additional data related to Aficamten
2M ago
Cytokinetics Announces Key Decisions at Annual Meeting
Premium
Company Announcements
Cytokinetics Announces Key Decisions at Annual Meeting
2M ago
Cytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
PremiumRatingsCytokinetics’ Promising Phase 3 Trial Results and Market Potential Justify Buy Rating
2M ago
Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
Premium
Ratings
Cytokinetics’ Aficamten Gains Competitive Edge with Successful Phase 3 Study, Strengthening Market Position
2M ago
Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis
Premium
Ratings
Cytokinetics’ Aficamten Shows Promise as First-Line Treatment for oHCM, Earning Buy Rating from Joseph Pantginis
2M ago
Cytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
PremiumRatingsCytokinetics Buy Rating: Strategic Developments and Market Opportunities Drive Optimism Despite FDA Delay
3M ago
Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
Premium
Ratings
Cytokinetics: Strong Financials and Promising Pipeline Drive Buy Rating
3M ago
Cytokinetics price target lowered to $80 from $86 at Citi
Premium
The Fly
Cytokinetics price target lowered to $80 from $86 at Citi
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100